shutterstock_1501091933_michael_vi
Michael Vi / Shutterstock.com
7 March 2023Big PharmaLiz Hockley

Genentech seeks ‘tens of millions in unpaid royalties’ in licence dispute

The Roche subsidiary says the licensee owes payments on “stockpile” of MS drug Tysabri.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
17 January 2022   Genentech has gained a win in a suit claiming that its haemophilia treatment Hemlibra infringes a patent owned by Takeda subsidiary, Baxalta, after a US federal judge held that parts of the patent were invalid.
Big Pharma
28 August 2020   Genentech and Chugai Pharmaceutical will have to face claims that its haemophilia drug Hemlibra (emicizumab-kxwh) infringed a patent owned by Takeda subsidiary Baxalta.

More on this story

Americas
17 January 2022   Genentech has gained a win in a suit claiming that its haemophilia treatment Hemlibra infringes a patent owned by Takeda subsidiary, Baxalta, after a US federal judge held that parts of the patent were invalid.
Big Pharma
28 August 2020   Genentech and Chugai Pharmaceutical will have to face claims that its haemophilia drug Hemlibra (emicizumab-kxwh) infringed a patent owned by Takeda subsidiary Baxalta.

More on this story

Americas
17 January 2022   Genentech has gained a win in a suit claiming that its haemophilia treatment Hemlibra infringes a patent owned by Takeda subsidiary, Baxalta, after a US federal judge held that parts of the patent were invalid.
Big Pharma
28 August 2020   Genentech and Chugai Pharmaceutical will have to face claims that its haemophilia drug Hemlibra (emicizumab-kxwh) infringed a patent owned by Takeda subsidiary Baxalta.